Kiadis Pharma obtains SME status from EMEA
(NL version) | go back
Groningen, 21 July 2007 – Oncology focused pharmaceutical product development company Kiadis Pharma announced today that the European Agency for the Evaluation of Medicinal Products (EMEA) has granted the company the SME (Small and Medium Sized Enterprises) status. This status for medical companies provides access to provisions for administrative and financial assistance. Kiadis Pharma will use this status to support the development of novel treatments for significant unmet medical needs in the field of bone marrow transplants and the treatment of aggressive cancers.
The SME program is an EMEA initiative to address the needs of small and medium sized companies who are developing medicinal products in Europe. Companies with SME status can receive assistance, information and training from dedicated EMEA employees. These companies are also eligible for reduced or deferred fees associated with regulatory submissions, scientific advice and inspections.
The SME status will immediately benefit Kiadis Pharma by facilitating the regulatory filing processes for the companies most advanced products in clinical development. Kiadis Pharma’s lead products include ATIR™ under development for a treatment that may enable end stage blood cancer patients to receive bone marrow transplants, including donor immune cells from mismatched donors. ATIR selectively eliminates cells from donors graft that can cause acute Graft-versus-Host-Disease. Rhitol™ under development for treatment of severe, steroid resistant chronic Graft-versus-Host-Disease and Reviroc™ for elimination of blood cancer cells from autologous grafts.
